The startup operates a pharmaceutical research and drug development firm focused on creating targeted therapies for patients with rare and intractable diseases, particularly in pediatrics and oncology. By utilizing advanced biopharmaceutical techniques, the company aims to address the unmet medical needs of these patient populations through the development of specialized treatment options.
Funding
Funding not disclosed
Founders
Product
Problem
Many patients in Japan, particularly those with rare or intractable diseases and pediatric conditions, lack access to innovative therapies available in Western markets due to the complexities and costs associated with bringing these drugs to the Japanese market. Emerging biopharmaceutical companies (EBPs) with promising new drugs often lack the resources or understanding of the Japanese market to navigate the regulatory and clinical development pathways necessary for approval. This results in a "drug loss" where potentially life-changing treatments are not available to Japanese patients.
Solution
LinDo K.K. operates as a pharmaceutical seed incubator, focusing on in-licensing novel therapeutic drugs for rare diseases, intractable conditions, and specific cancers from emerging biopharmaceutical companies (EBPs) in Europe and the US. LinDo specializes in navigating the Japanese regulatory landscape, managing clinical development, and securing market access for these promising therapies. By partnering with MIJ (Medical Incubator Japan), LinDo strengthens its ability to identify and evaluate promising drug candidates. LinDo's lean development management system and experienced team facilitate efficient clinical trials and accelerate the availability of innovative treatments to Japanese patients, addressing critical unmet medical needs. The company focuses on areas where existing treatments provide insufficient therapeutic outcomes, aiming to provide patients and healthcare professionals with access to a wider range of treatment options.
Target Audience
LinDo's primary beneficiaries are Japanese patients suffering from rare diseases, intractable conditions, and specific cancers, particularly in the pediatric population, who currently lack access to innovative therapies available in other global markets, as well as the physicians and healthcare professionals who treat these patients.
Features
- Strategic in-licensing of drug candidates from emerging biopharmaceutical companies (EBPs) with innovative technologies.
- Specialization in navigating the Japanese regulatory approval process for pharmaceuticals.
- Management of clinical development programs, including trial design, execution, and data analysis.
- Collaboration with Medical Incubator Japan (MIJ) to enhance drug candidate identification and evaluation.
- Focus on therapeutic areas with high unmet needs, including rare diseases, intractable conditions, pediatric diseases, and specific cancers.
- Lean development management system to optimize efficiency and reduce development costs.
- Partnership network for comprehensive support from clinical trials to marketing and logistics.